Literature DB >> 11683742

Readmissions after pancreatoduodenectomy.

R C van Geenen1, T M van Gulik, O R Busch, L T de Wit, H Obertop, D J Gouma.   

Abstract

BACKGROUND: Readmission after pancreatoduodenectomy because of tumour recurrence or surgery-related complications can adversely affect patient outcome.
METHODS: From October 1992 to June 1999, 283 consecutive resections were performed (243 for malignant disease and 40 for benign disease). The hospital mortality rate was 1 per cent (three of 283). All readmissions were analysed with regard to indication, treatment and outcome.
RESULTS: One hundred and six patients (38 per cent) were readmitted, 64 (60 per cent) because of tumour recurrence and indications such as gastrointestinal obstruction (n = 19), biliary obstruction (n = 15) and pain (n = 21), of whom 30 patients (47 per cent) were in a preterminal condition. Median hospital stay and hospital-free survival after discharge were 14 and 51 days respectively. Median survival after surgical treatment (n = 14) was 58 days, and ascites was significantly associated with poor survival. Forty-seven (44 per cent) of the patients were readmitted for surgical complications such as abscess (n = 11), fistula (n = 8) and gastrointestinal obstruction (n = 8). Median hospital stay was 15 days and median hospital-free survival after discharge was 1035 days.
CONCLUSION: Readmission after pancreatoduodenectomy was common (38 per cent), 60 per cent for tumour recurrence and 44 per cent for surgery-related complications. Survival after surgical bypass procedures for tumour recurrence was limited, particularly when ascites was present. Patients readmitted for complications of surgery had a good prognosis.

Entities:  

Mesh:

Year:  2001        PMID: 11683742     DOI: 10.1046/j.0007-1323.2001.01900.x

Source DB:  PubMed          Journal:  Br J Surg        ISSN: 0007-1323            Impact factor:   6.939


  13 in total

1.  Hospital readmission after pancreaticoduodenectomy.

Authors:  Dawn M Emick; Taylor S Riall; John L Cameron; Jordan M Winter; Keith D Lillemoe; Joann Coleman; Patricia K Sauter; Charles J Yeo
Journal:  J Gastrointest Surg       Date:  2006-11       Impact factor: 3.452

2.  Thirty days are inadequate for assessing readmission following complex hepatopancreatobiliary procedures.

Authors:  Maria S Altieri; Jie Yang; Donglei Yin; Konstantinos Spaniolas; Mark Talamini; Aurora Pryor
Journal:  Surg Endosc       Date:  2018-12-10       Impact factor: 4.584

3.  Extended follow-up and outcomes of patients undergoing pancreaticoduodenectomy for nonmalignant disease.

Authors:  Nicholas Thomas Orfanidis; David E Loren; Carmi Santos; Eugene P Kennedy; Ali A Siddiqui; Harish Lavu; Charles J Yeo; Thomas E Kowalski
Journal:  J Gastrointest Surg       Date:  2011-11-05       Impact factor: 3.452

4.  Understanding hospital readmissions after pancreaticoduodenectomy: can we prevent them?: a 10-year contemporary experience with 1,173 patients at the Massachusetts General Hospital.

Authors:  Zhi Ven Fong; Cristina R Ferrone; Sarah P Thayer; Jennifer A Wargo; Klaus Sahora; Kimberly J Seefeld; Andrew L Warshaw; Keith D Lillemoe; Mathew M Hutter; Carlos Fernández-Del Castillo
Journal:  J Gastrointest Surg       Date:  2013-09-04       Impact factor: 3.452

5.  C-Reactive Protein on Postoperative Day 1 Is a Reliable Predictor of Pancreas-Specific Complications After Pancreaticoduodenectomy.

Authors:  Théophile Guilbaud; David Jérémie Birnbaum; Coralie Lemoine; Mircea Chirica; Olivier Risse; Stéphane Berdah; Edouard Girard; Vincent Moutardier
Journal:  J Gastrointest Surg       Date:  2018-01-04       Impact factor: 3.452

6.  Factors associated with recidivism following pancreaticoduodenectomy.

Authors:  Sanjeet S Grewal; Rebecca J McClaine; Nathan Schmulewitz; Mohammed A Alzahrani; Dennis J Hanseman; Jeffery J Sussman; Milton Smith; Kyuran A Choe; Olugbenga Olowokure; Michelle Mierzwa; Syed A Ahmad
Journal:  HPB (Oxford)       Date:  2011-10-26       Impact factor: 3.647

7.  A 6-day clinical pathway after a pancreaticoduodenectomy is feasible, safe and efficient.

Authors:  Dustin M Walters; Patrick McGarey; Damien J LaPar; Aimee Strong; Elizabeth Good; Reid B Adams; Todd W Bauer
Journal:  HPB (Oxford)       Date:  2012-12-02       Impact factor: 3.647

8.  Patient readmission and mortality after surgery for hepato-pancreato-biliary malignancies.

Authors:  Eric B Schneider; Omar Hyder; Christopher L Wolfgang; Kenzo Hirose; Michael A Choti; Martin A Makary; Joseph M Herman; John L Cameron; Timothy M Pawlik
Journal:  J Am Coll Surg       Date:  2012-08-24       Impact factor: 6.113

9.  Tracking early readmission after pancreatectomy to index and nonindex institutions: a more accurate assessment of readmission.

Authors:  Jeffrey J Tosoian; Caitlin W Hicks; John L Cameron; Vicente Valero; Frederic E Eckhauser; Kenzo Hirose; Martin A Makary; Timothy M Pawlik; Nita Ahuja; Matthew J Weiss; Christopher L Wolfgang
Journal:  JAMA Surg       Date:  2015-02       Impact factor: 14.766

10.  Readmission after pancreatectomy for pancreatic cancer in Medicare patients.

Authors:  Deepthi M Reddy; Courtney M Townsend; Yong-Fang Kuo; Jean L Freeman; James S Goodwin; Taylor S Riall
Journal:  J Gastrointest Surg       Date:  2009-09-16       Impact factor: 3.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.